ACNP 59Th Annual Meeting: Poster Session II
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Zuranolone | Medchemexpress
Inhibitors Product Data Sheet Zuranolone • Agonists Cat. No.: HY-103040 CAS No.: 1632051-40-1 Molecular Formula: C₂₅H₃₅N₃O₂ • Molecular Weight: 409.56 Screening Libraries Target: GABA Receptor Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (244.16 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.4416 mL 12.2082 mL 24.4164 mL Stock Solutions 5 mM 0.4883 mL 2.4416 mL 4.8833 mL 10 mM 0.2442 mL 1.2208 mL 2.4416 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.10 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution 4. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: 2.5 mg/mL (6.10 mM); Suspended solution; Need ultrasonic 5. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution BIOLOGICAL ACTIVITY Description Zuranolone is an orally active and potent neuroactive steroid positive allosteric modulator of GABAA receptor, with EC50s of [1] 296 and 163 nM for α1β2γ2 and α4β3δ GABAA receptors, respectively . -
The Ethics of Psychedelic Medicine: a Case for the Reclassification of Psilocybin for Therapeutic Purposes
THE ETHICS OF PSYCHEDELIC MEDICINE: A CASE FOR THE RECLASSIFICATION OF PSILOCYBIN FOR THERAPEUTIC PURPOSES By Akansh Hans A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Bioethics Baltimore, Maryland May 2021 © 2021 Akansh Hans All Rights Reserved I. Abstract Our current therapeutic mental health paradigms have been unable to adequately handle the mental illness crisis we are facing. We ought to ‘use every tool in our toolbox’ to help individuals heal, and the tool we should be utilizing right now is Psilocybin. Although it is classified as a Schedule I drug, meaning that it is believed to have a high potential for abuse, no accepted medical uses, and a lack of safety when used under medical supervision, Psilocybin is not addictive and does not have a high potential for abuse when used safely under medical supervision. For these reasons alone, Psilocybin deserves a reclassification for therapeutic purposes. However, many individuals oppose Psilocybin-assisted psychotherapy on ethical grounds or due to societal concerns. These concerns include: a potential change in personal identity, a potential loss of human autonomy, issues of informed consent, safety, implications of potential increased recreational use, and distributive justice and fairness issues. Decriminalization, which is distinct from reclassification, means that individuals should not be incarcerated for the use of such plant medicines. This must happen first to stop racial and societal injustices from continuing as there are no inherently ‘good’ or ‘bad’ drugs. Rather, these substances are simply chemicals that humans have developed relationships with. As is shown in this thesis, the ethical implications and risks of psychedelic medicine can be adequately addressed and balanced, and the benefits of Psilocybin as a healing tool far outweigh the risks. -
Serotonergic Psychedelic Drugs LSD and Psilocybin Reduce the Hierarchical Differentiation of Unimodal and Transmodal Cortex
bioRxiv preprint doi: https://doi.org/10.1101/2020.05.01.072314; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex Manesh Girna, Leor Rosemanb, Boris Bernhardta, Jonathan Smallwoodc, Robin Carhart-Harrisb, R. Nathan Sprenga,d,e,f a Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. b Centre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK c Department of Psychology, University of York, York, UK d Departments of Psychiatry and Psychology, McGill University, Montreal, QC, Canada e Douglas Mental Health University Institute, Verdun, QC, Canada f McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada 1To whom correspondence should be addressed. Correspondence: [email protected] Laboratory of Brain and Cognition Montreal Neurological Institute and Hospital 3801 Rue Université, Montréal, QC H3A 2B4 Conflicts of interest: none 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.01.072314; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract LSD and psilocybin are serotonergic psychedelic compounds with potential in the treatment of mental health disorders. -
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209 -
The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming Within a Large Database of Psychoactive Substance Reports
ORIGINAL RESEARCH published: 22 January 2018 doi: 10.3389/fnins.2018.00007 The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports Camila Sanz 1, Federico Zamberlan 1, Earth Erowid 2, Fire Erowid 2 and Enzo Tagliazucchi 1,3* 1 Departamento de Física, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Erowid Center, Grass Valley, CA, United States, 3 Brain and Spine Institute, Paris, France Ever since the modern rediscovery of psychedelic substances by Western society, Edited by: several authors have independently proposed that their effects bear a high resemblance Rick Strassman, to the dreams and dreamlike experiences occurring naturally during the sleep-wake University of New Mexico School of cycle. Recent studies in humans have provided neurophysiological evidence supporting Medicine, United States this hypothesis. However, a rigorous comparative analysis of the phenomenology (“what Reviewed by: Matthias E. Liechti, it feels like” to experience these states) is currently lacking. We investigated the semantic University Hospital Basel, Switzerland similarity between a large number of subjective reports of psychoactive substances and Michael Kometer, University of Zurich, Switzerland reports of high/low lucidity dreams, and found that the highest-ranking substance in *Correspondence: terms of the similarity to high lucidity dreams was the serotonergic psychedelic lysergic Enzo Tagliazucchi acid diethylamide (LSD), whereas the highest-ranking in terms of the similarity to dreams [email protected] of low lucidity were plants of the Datura genus, rich in deliriant tropane alkaloids. Specialty section: Conversely, sedatives, stimulants, antipsychotics, and antidepressants comprised most This article was submitted to of the lowest-ranking substances. -
View Presentation
Investor Presentation June 2020 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “opportunity”, “goal”, “potential,” or “continue,” and other similar expressions. • Forward-looking statements in this presentation include statements regarding: our plans and expectations for ZULRESSO, including our revenue expectations and the factors that may impact revenues; our expectations as to the development and regulatory path forward and filing requirements for zuranolone; our development plans, goals and strategy for our product candidates and the potential results of our development efforts; the anticipated timing of clinical trial initiation and reporting of results, including our belief as to our ability to mitigate the possible impact of the COVID-19 pandemic on our clinical development timelines; the potential profile and benefit of our product candidates; our belief in the potential of our product candidates in various indications; the estimated number of patients with the disorders and diseases we are studying or plan to study; our financial expectations, including with respect to year-end cash; our belief that existing cash will support operations into 2022; and our expectations as to the goals, opportunity and potential for our business. • These forward-looking statements are neither promises -
DMT Alters Cortical Travelling Waves Andrea Alamia1‡*, Christopher Timmermann2,3‡*, David J Nutt3, Rufin Vanrullen1,4†, Robin L Carhart-Harris3†
RESEARCH ARTICLE DMT alters cortical travelling waves Andrea Alamia1‡*, Christopher Timmermann2,3‡*, David J Nutt3, Rufin VanRullen1,4†, Robin L Carhart-Harris3† 1Cerco, CNRS Universite´ de Toulouse, Toulouse, France; 2Computational, Cognitive and Clinical Neuroscience Laboratory (C3NL), Faculty of Medicine, Imperial College, London, United Kingdom; 3Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom; 4Artificial and Natural Intelligence Toulouse Institute (ANITI), Toulouse, France Abstract Psychedelic drugs are potent modulators of conscious states and therefore powerful tools for investigating their neurobiology. N,N, Dimethyltryptamine (DMT) can rapidly induce an extremely immersive state of consciousness characterized by vivid and elaborate visual imagery. Here, we investigated the electrophysiological correlates of the DMT-induced altered state from a pool of participants receiving DMT and (separately) placebo (saline) while instructed to keep their eyes closed. Consistent with our hypotheses, results revealed a spatio-temporal pattern of cortical activation (i.e. travelling waves) similar to that elicited by visual stimulation. Moreover, the typical top-down alpha-band rhythms of closed-eyes rest were significantly decreased, while the bottom- up forward wave was significantly increased. These results support a recent model proposing that *For correspondence: psychedelics reduce the ‘precision-weighting of priors’, thus altering the balance of top-down -
Zuranolone—An Investigational Oral Neuroactive Steroid and Positive
Expert Interview Psychiatric Disorders Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder Handan Gunduz-Bruce Sage Therapeutics, Inc., Cambridge, MA, USA Handan Gunduz-Bruce Handan Gunduz-Bruce is Senior Medical Director at Sage Therapeutics, Inc. and Assistant Clinical Professor of Psychiatry at Yale School of Medicine. She received her medical degree from the Istanbul Medical Faculty in 1991 and then completed her residency in psychiatry, followed by a fellowship in clinical neuroscience at the Long Island Jewish Medical Center of Albert Einstein College of Medicine. Earlier in her academic career, Dr. Gunduz-Bruce’s research focused on the longitudinal course and pharmacological treatment of schizophrenia. Her later research included pathophysiology studies of schizophrenia and depression with a focus on the N-methyl-D-aspartate (NMDA) receptor function and GABAergic mechanisms using electrophysiological, imaging and biomarker approaches. More recently, she received her MBA degree in Leadership in Healthcare from Yale School of Management. Since the beginning of her tenure at Sage Therapeutics, Dr. Gunduz-Bruce has contributed to the approval of ZULRESSOTM, the first pharmacological treatment for postpartum depression in adults, and continues to oversee the development of zuranolone, an investigational oral neuroactive steroid and positive allosteric modulator of GABAA receptors, for postpartum depression and major -
Horizon Scanning Status Report Volume 2, Issue 1 March 2020
PCORI Health Care Horizon Scanning System Horizon Scanning Status Report Volume 2, Issue 1 March 2020 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, PA-C Marcus Lynch, PhD Misha Mehta, MS Brian Wilkinson, MA Donna Beales, MLIS Jennifer De Lurio, MS Eloise DeHaan, BS Eileen Erinoff, MSLIS Maria Middleton, MPH Diane Robertson, BA Kelley Tipton, MPH Rosemary Walker, MLIS Karen Schoelles, MD, SM Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the Horizon Scanning System has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. -
Systematic Review Randomised Controlled Trials Meta-Analysis
9 July 2021 Systematic Review Care farms: can they help with depression, anxiety and quality of life? Appraisal of a recent Campbell systematic review exploring the impact of care farms on quality of life, depression and anxiety among different population groups. Meta-analysis New evidence on treatments for symptoms of depression in dementia Appraisal of a recent review on the efficacy of interventions for depression in people with dementia, which identified several non-drug treatments that can have a meaningful effect on depressive symptoms in dementia. Randomised Controlled Trials Turn on, or tune out? Is psilocybin assisted therapy close to becoming a first- line treatment for depression? Summary of a recent RCT on the effectiveness of psilocybin assisted therapy versus escitalopram assisted therapy for major depressive disorder. Could a decision support tool help to guide mental health treatment in primary care? Review of a recent randomised controlled trial on the clinical efficacy of a Decision Support Tool (Link-me) to “guide the intensity of mental health care in primary practice”. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial In this phase 3 RCT of women with PPD, zuranolone achieved its primary end point of a statistically significant change from baseline in HAMD-17 total score compared with placebo at day 15. Zuranolone showed rapid (by day 3), sustained (all measured time points through day 45), and clinically meaningful improvements in depressive symptoms, anxiety, and global and maternal functioning and was generally well tolerated. Follow Website Contact us 9 July 2021 Studies Alcohol and bipolar: how does heavy alcohol use predict the course of bipolar disorder? Review of a recent study on the patterns and clinical correlates of lifetime alcohol consumption in women and men with bipolar disorder. -
Effects of Ayahuasca on Sensory and Sensorimotor Gating in Humans As Measured by P50 Suppression and Prepulse Inhibition of the Startle Reflex, Respectively
Psychopharmacology (2002) 165:18–28 DOI 10.1007/s00213-002-1237-5 ORIGINAL INVESTIGATION Jordi Riba · Antoni Rodrguez-Fornells · Manel J. Barbanoj Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively Received: 2 January 2002 / Accepted: 15 July 2002 / Published online: 12 October 2002 Springer-Verlag 2002 Abstract Rationale: Ayahuasca, a South American psy- alone and 60 ms, 120 ms, 240 ms and 2000 ms prepulse- chotropic plant tea, combines the psychedelic agent and to-pulse intervals) recordings were undertaken at 1.5 h 5-HT2A/2C agonist N,N-dimethyltryptamine (DMT) with and 2 h after drug intake, respectively. Results: Ayahuasca b-carboline alkaloids showing monoamine oxidase-in- produced diverging effects on each of the two gating hibiting properties. Current human research with psyche- measures evaluated. Whereas significant dose-dependent delics and entactogens has explored the possibility that reductions of P50 suppression were observed after drugs displaying agonist activity at the 5-HT2A/2C sites ayahuasca, no significant effects were found on the temporally disrupt inhibitory neural mechanisms thought startle response, its habituation rate, or on PPI at any of to intervene in the normal filtering of information. the prepulse-to-pulse intervals studied. Conclusion: The Suppression of the P50 auditory evoked potential (AEP) present findings indicate, at the doses tested, a decre- and prepulse inhibition of startle (PPI) are considered mental effect of ayahuasca on sensory gating, as operational measures of sensory (P50 suppression) and measured by P50 suppression, and no distinct effects on sensorimotor (PPI) gating. -
Psilocybin-Assisted Therapy: a Double-Blind Randomized Controlled Trial
Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale School of Medicine Physician Associate Program Theses School of Medicine 4-1-2019 Psilocybin-Assisted Therapy: A Double-Blind Randomized Controlled Trial Katherine Gruppo Yale Physician Associate Program, [email protected] Follow this and additional works at: https://elischolar.library.yale.edu/ysmpa_theses Part of the Medicine and Health Sciences Commons Recommended Citation Gruppo, Katherine, "Psilocybin-Assisted Therapy: A Double-Blind Randomized Controlled Trial" (2019). Yale School of Medicine Physician Associate Program Theses. 51. https://elischolar.library.yale.edu/ysmpa_theses/51 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Medicine Physician Associate Program Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. PSILOCYBIN-ASSISTED THERAPY: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL A Thesis Presented to The Faculty of the School of Medicine Yale University In Candidacy for the Degree of Master of Medical Science April 2019 Katherine Gruppo, PA-SII John Krystal, MD Class of 2019 Robert L. McNeil, Jr. Professor of Yale Physician Associate Program Translational Research and Professor of Psychiatry, Neuroscience; Chair, Department of Psychiatry; Chief of Psychiatry, Yale-New